Assessment of GeneXpert GxAlert platform for multi-drug resistant tuberculosis diagnosis and patients’ linkage to care in Tanzania

Autor: Rudovick Kazwala, Dong-Jin Kim, Sayoki Mfinanga, Issack Lekule, Johnson Lymo, Fausta Mosha, Esther Ngadaya, Pammla Petrucka, Nicholaus P. Mnyambwa, Godfather Kimaro
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Adult
medicine.medical_specialty
Rifampicin resistant
Psychological intervention
Multi-drug resistant tuberculosis (MDR-TB)
lcsh:Medicine
GeneXpert
Rifampicin resistance
Tanzania
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
0302 clinical medicine
Internal medicine
Drug Resistance
Multiple
Bacterial
Tuberculosis
Multidrug-Resistant
medicine
Humans
Patient Navigation
030212 general & internal medicine
GxAlert
lcsh:Science (General)
Antibiotics
Antitubercular
lcsh:QH301-705.5
Linkage (software)
030505 public health
GeneXpert MTB/RIF
biology
business.industry
Multi-drug-resistant tuberculosis
lcsh:R
Tuberculosis (TB) diagnosis
General Medicine
Patient Acceptance of Health Care
biology.organism_classification
medicine.disease
Resistant tuberculosis
3. Good health
Research Note
lcsh:Biology (General)
MDR-TB treatment
Rifampin
0305 other medical science
business
lcsh:Q1-390
Zdroj: BMC Research Notes, Vol 11, Iss 1, Pp 1-6 (2018)
BMC Research Notes
ISSN: 1756-0500
DOI: 10.1186/s13104-018-3235-7
Popis: Objective The gap between patients diagnosed with multi-drug resistant tuberculosis (MDR-TB) and enrolment in treatment is one of the major challenges in tuberculosis control programmes. A 4-year (2013–2016) retrospective review of patients’ clinical data and subsequent in-depth interviews with health providers were conducted to assess the effectiveness of the GeneXpert GxAlert platform for MDR-TB diagnosis and its impact on linkage of patients to care in Tanzania. Results A total of 782 new rifampicin resistant cases were notified, but only 242 (32.3%) were placed in an MDR-TB regimens. The remaining 540 (67.07%) patients were not on treatment, of which 103 patients had complete records on the GxAlert database. Of the 103 patients: 39 were judged as untraceable; 27 died before treatment; 12 were treated with first-line anti-TBs; 9 repeat tests did not show rifampicin resistance; 15 were not on treatment due to communication breakdown, and 1 patient was transferred outside the country. In-depth interviews with health providers suggested that the pre-treatment loss for the MDR-TB patients was primarily attributed to health system and patients themselves. We recommend strengthening the health system by developing and implementing well-defined interventions to ensure all diagnosed MDR-TB patients are accurately reported and timely linked to treatment.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje